Consistent with our finding are the results reported by Villedieu et al. [66], showing that acquisition of cisplatin resistance in OAW42-R ovarian carcinoma cells is associated with loss of ERK activation in response to cisplatin. This evidence concerns the gene MAPK1 and ovarian carcinoma.